Elanco Animal Health, Inc. Stock News

GREENFIELD, Ind. , Sept. 13, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today provided an update on its relationship with contract manufacturing supplier, TriRx Speke Ltd (TriRx).

GREENFIELD, Ind. , Aug. 28, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) will attend the Morgan Stanley 22nd Annual Global Healthcare Conference, September 4-5, 2024.

Company's broad spectrum parasiticide on-track for October U.S. approval and first quarter 2025 launch GREENFIELD, Ind. , Aug. 20, 2024 /PRNewswire/ -- Elanco Animal Health Incorporated (NYSE: ELAN) today announced the U.S. Food and Drug Administration (FDA) has completed its review of all major and minor technical sections for Credelio Quattro, and the final 60-day administrative review is und...

After an acquisition of Bayer Animal Health in 2020, Elanco has made progress in paying down debt. Robust pipeline with six potential blockbuster products to be launched in 2024 and 2025. Improving cash flow and financial metrics.

Study finds that the aggressive lone star tick is no match for Credelio GREENFIELD, Ind. , Aug. 15, 2024 /PRNewswire/ -- Parasites & Vectors , a leading peer-reviewed journal focused on parasites and vector-borne pathogens published the results of a head-to-head study demonstrating that Credelio, a prescription flea and tick protection product from Elanco Animal Health, has the fastest initial ...

Elanco Animal Health (NYSE:ELAN ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Katy Grissom - Head of Investor Relations Jeffrey Simmons - President & Chief Executive Officer Todd Young - Executive Vice President & Chief Financial Officer Conference Call Participants Jon Block - Stifel Michael Ryskin - Bank of America Umer Raffat - Evercore ISI Chris Schott - ...

Raises Full Year Revenue and Maintains Adjusted EBITDA Guidance Excluding Aqua Divestiture Second Quarter 2024 Financial Results Revenue of $1,184 million Reported Net Loss of $50 million, Adjusted Net Income of $147 million Adjusted EBITDA of $275 million, or 23.2% of Revenue Reported EPS of $(0.10), Adjusted EPS of $0.30 Net leverage ratio of 5.6x Adjusted EBITDA Year over year growth rates a...

SAN FRANCISCO, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Elanco Animal Health Incorporated (NYSE: ELAN) investors who suffered substantial losses to submit your losses now.